These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 25561335

  • 1. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
    Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
    [Abstract] [Full Text] [Related]

  • 2. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).
    Mendes RE, Sader HS, Smart JI, Castanheira M, Flamm RK.
    Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1013-1017. PubMed ID: 28111724
    [Abstract] [Full Text] [Related]

  • 3. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 4. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR, Smith CJ, Flamm RK, Mendes RE.
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [Abstract] [Full Text] [Related]

  • 5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE.
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE, Moet GJ, Janechek MJ, Jones RN.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR, Lainhart W, Wallace MA, Shupe A, Burnham CD.
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [Abstract] [Full Text] [Related]

  • 8. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [Abstract] [Full Text] [Related]

  • 9. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
    Marconescu P, Graviss EA, Musher DM.
    Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
    [Abstract] [Full Text] [Related]

  • 10. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ, Flamm RK, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [Abstract] [Full Text] [Related]

  • 11. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN.
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [Abstract] [Full Text] [Related]

  • 13. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA, Nichol K, Zhanel GG.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [Abstract] [Full Text] [Related]

  • 14. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
    Pfaller MA, Rhomberg PR, Huband MD, Flamm RK.
    Antimicrob Agents Chemother; 2017 Mar 15; 61(3):. PubMed ID: 27993854
    [Abstract] [Full Text] [Related]

  • 15. A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin.
    Fujimura S, Nakano Y, Watanabe A.
    J Infect Chemother; 2014 Dec 15; 20(12):752-6. PubMed ID: 25287155
    [Abstract] [Full Text] [Related]

  • 16. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD, Pawlak J, Johnson LB.
    J Antimicrob Chemother; 2007 Aug 15; 60(2):406-9. PubMed ID: 17586562
    [Abstract] [Full Text] [Related]

  • 17. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.
    J Glob Antimicrob Resist; 2017 Dec 15; 11():4-7. PubMed ID: 28735053
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC, Sancak B, Gür D.
    Microb Drug Resist; 2015 Oct 15; 21(5):537-44. PubMed ID: 25919019
    [Abstract] [Full Text] [Related]

  • 20. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2010 Oct 15; 36(4):374-9. PubMed ID: 20598860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.